Gender-based Violence Area of Responsibility Working Group July 2010
Inter-Agency Task Team on HIV and Young People
Guidance Brief
Accessed: 09.11.2019
12-13 December 2016
Global Action Plan on HIV Drug Resistance - Webinars 12-13 December 2016
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested HIV positive i...n randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
3rd Edition – July 2017
www.msfaccess.org
Policy Brief
Accessed: 20.11.2019
Original Research
Rev Panam Salud Publica 43, 2019 | www.paho.org/journal | https://doi.org/10.26633/RPSP.2019.31